At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 130 enrolled
Drug / intervention
Lasmiditan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled, Group Sequential, Adaptive Treatment Assignment Study of Intravenous COL-144 (LY573144) in the Acute Treatment of Migraine
In Brief
A Phase 2 clinical trial evaluating Lasmiditan and Placebo for Migraine. Completed, enrolled 130 participants across 3 sites in 3 countries.
Detailed Summary
This study evaluates the efficacy of a range of intravenous doses of COL-144 in the treatment of migraine headache in order to select a dose range for further studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesFinland, Germany, Netherlands
CollaboratorsCoLucid Pharmaceuticals
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartNov 2006
Primary CompletionJun 2007
TodayJul 2026
First PostedOct 6, 2006
Enrollment StartNov 1, 2006
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 19.7 years ago
Interventions
Lasmiditandrug
Administered as intravenous infusion
Placebodrug
Administered as intravenous infusion